Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
2.510
-0.160 (-5.99%)
At close: Apr 1, 2025, 4:00 PM
2.529
+0.019 (0.76%)
After-hours: Apr 1, 2025, 4:23 PM EDT
Achieve Life Sciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Achieve Life Sciences stock have an average target of 15.75, with a low estimate of 11 and a high estimate of 20. The average target predicts an increase of 527.49% from the current stock price of 2.51.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for Achieve Life Sciences stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +378.09% | Nov 14, 2024 |
| Raymond James | Raymond James | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +696.81% | Sep 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $11 | Buy | Reiterates | $11 | +338.25% | Aug 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 → $11 | Buy | Maintains | $18 → $11 | +338.25% | May 13, 2024 |
| JonesTrading | JonesTrading | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +696.81% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
from 330.89M
Revenue Next Year
n/a
EPS This Year
-1.25
from -1.24
EPS Next Year
-1.15
from -1.25
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 52.7M | 124.0M | ||
| Avg | n/a | 29.1M | 101.6M | ||
| Low | n/a | 8.4M | 79.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 325.6% | ||
| Avg | - | - | 248.5% | ||
| Low | - | - | 171.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.98 | -0.37 | 0.22 | ||
| Avg | -1.25 | -1.15 | -0.22 | ||
| Low | -1.59 | -1.57 | -1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.